Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients

Table 2 Intrahepatic HBV DNA level in chronic HBV patients and HBV genotypes mean ± SD

Parameter	Intrahepatic HBV DNA< 5 log10 (n = 38)	Intrahepatic HBV DNA≥ 5 log10 (n = 33)	HBV genotypesGenotype C group (n = 61) Genotype B (n = 10)
Knodell score: pretreatment	7.6 ± 4.0	8.2 ± 4.1	8.1 ± 4.1	5.7 ± 3.2
post-treatment	4.8 ± 2.2a	7.4 ± 4.1	6.0 ± 3.4a	5.4 ± 3.1
Intrahepatic HBV DNA (log10): pretreatment	5.8 ± 1.0	6.3 ± 0.9	6.1 ± 0.9	5.6 ± 1.5
post-treatment	3.8 ± 0.9a	6.1 ± 0.7	4.9 ± 1.4a	4.7 ± 1.2
Serum HBV DNA (log10): pretreatment	7.6 ± 1.0	7.8 ± 1.3	7.7 ± 1.2	7.6 ± 0.8
post-treatment	3.3 ± 0.7a	4.7 ± 1.4a	4.05 ± 1.3a	4.9 ± 1.2a
Off- treatment 24 wk	5.1 ± 1.4	5.2 ± 1.7	5.1 ± 1.6	4.3 ± 1.3
ALT (nkat/L): pretreatment	4342 ± 2788	2571 ± 1519	3390 ± 2438	4509 ± 2338
post-treatment	634 ± 567a	1135 ± 1052	912 ± 918a	551 ± 236a
Off-treatment 24 wk	1519 ± 1519	1637 ± 1369	1503 ± 1336	1987 ± 1720
Off-treatment 24 wk virological response rate	23.7% (9/38)	27.3% (9/33)	31.1% (19/51)	30% (3/10)
Off-treatment 24 wk ALT normalization rate	16.7% (15/38)	13.3% (10/33)	39.3% (24/51)	30% (3/10)

^aP < 0.05 vs pretreatment.